Alligator Bioscience Overview

  • Year Founded
  • 2001

Year Founded

  • Status
  • Public

  • Employees
  • 11

Employees

  • Stock Symbol
  • ATORX

Stock Symbol

  • Investments
  • 2

Alligator Bioscience General Information

Description

Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs focused on the CD40 receptor. The company's main drug candidate, mitazalimab, is currently under development as a therapy for metastatic pancreatic cancer patients. Its development pipeline also comprises: ATOR-4066, a bispecific antibody targeting CD40, as well as CEACAM5 (carcinoembryonic antigen 5), a protein found in certain tumors; and certain externally developed programs like HLX22 and ALG.APV-527. Geographically, the company generates maximum revenue from Belgium (mainly through out-licensing), and also has its presence in Sweden and Finland.

Contact Information

Formerly Known As
Alligator Holdings
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • Medicon Village
  • Scheeletorget 1
  • 223 81 Lund
  • Sweden
+46 046-540
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Stock Exchange
STO
Vertical(s)
Corporate Office
  • Medicon Village
  • Scheeletorget 1
  • 223 81 Lund
  • Sweden
+46 046-540

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Alligator Bioscience Stock Performance

As of 20-Nov-2026, Alligator Bioscience’s current market cap is $2.8M with 3.57B shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$2.8M 3.57B 35.3M -$0.06

Alligator Bioscience Financials Summary

As of 30-Sep-2026, Alligator Bioscience has a trailing 12-month revenue of $30.1K.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 3,182 19,561 13,750 34,807
Revenue 30 52 5,462 5,467
EBITDA (6,661) (549) (19,854) (22,532)
Net Income (8,738) (5,227) (22,115) (23,387)
Total Assets 8,944 12,020 9,456 11,852
Total Debt 2,779 4,689 16,387 1,655
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Alligator Bioscience Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Alligator Bioscience‘s full profile, request access.

Request a free trial

Alligator Bioscience Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Alligator Bioscience‘s full profile, request access.

Request a free trial

Alligator Bioscience Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody dru
Drug Discovery
Lund, Sweden
11 As of 2026

Cambridge, MA
 

San Francisco, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Alligator Bioscience Competitors (79)

One of Alligator Bioscience’s 79 competitors is Blueprint Medicines, a Formerly VC-backed company based in Cambridge, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Blueprint Medicines Formerly VC-backed Cambridge, MA
GT Biopharma Corporation San Francisco, CA
Alnylam Pharmaceuticals Formerly VC-backed Cambridge, MA
Damora Therapeutics ( Drug Discovery) Formerly VC-backed Waltham, MA
AVEO Oncology Formerly VC-backed Boston, MA
You’re viewing 5 of 79 competitors. Get the full list »

Alligator Bioscience Patents

Alligator Bioscience Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
GB-202507480-D0 Method of predicting responsiveness to therapy Pending 15-May-2025
GB-202410994-D0 Novel polypeptides Inactive 26-Jul-2024
GB-202401084-D0 Methods Inactive 26-Jan-2024
GB-202316390-D0 Combination therapies Inactive 26-Oct-2023
EP-4695291-A1 Combination therapies Pending 13-Apr-2023 C07K16/3007
To view Alligator Bioscience’s complete patent history, request access »

Alligator Bioscience Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Alligator Bioscience Investments & Acquisitions (2)

Alligator Bioscience’s most recent deal was a Later Stage VC with Peptinovo Biopharma for . The deal was made on 16-Dec-2024.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Peptinovo Biopharma 16-Dec-2024 Later Stage VC Drug Delivery
Atlas Therapeutics 23-Oct-2013 Merger/Acquisition Drug Discovery
To view Alligator Bioscience’s complete investments and acquisitions history, request access »

Alligator Bioscience ESG

Risk Overview

Risk Rating

Updated November, 30, 2024

41.58 | Severe Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 14,271

Rank

Percentile

Pharmaceuticals

Industry

of 908

Rank

Percentile

Biotechnology

Subindustry

of 434

Rank

Percentile

To view Alligator Bioscience’s complete esg history, request access »

Alligator Bioscience Affiliates

Subsidiaries (2)

Name Industry Location Year Founded
Atlas Therapeutics Stockholm, Sweden 2010
Alligator Bioscience (CD40 Agonist Antibody Mitazalimab) Lund, Sweden

Alligator Bioscience FAQs

  • When was Alligator Bioscience founded?

    Alligator Bioscience was founded in 2001.

  • Where is Alligator Bioscience headquartered?

    Alligator Bioscience is headquartered in Lund, Sweden.

  • What is the size of Alligator Bioscience?

    Alligator Bioscience has 11 total employees.

  • What industry is Alligator Bioscience in?

    Alligator Bioscience’s primary industry is Drug Discovery.

  • Is Alligator Bioscience a private or public company?

    Alligator Bioscience is a Public company.

  • What is Alligator Bioscience’s stock symbol?

    The ticker symbol for Alligator Bioscience is ATORX.

  • What is the current market cap of Alligator Bioscience?

    The current market capitalization of Alligator Bioscience is $2.8M.

  • What is Alligator Bioscience’s current revenue?

    The trailing twelve month revenue for Alligator Bioscience is $30.1K.

  • Who are Alligator Bioscience’s competitors?

    Blueprint Medicines, GT Biopharma, Alnylam Pharmaceuticals, Damora Therapeutics ( Drug Discovery), and AVEO Oncology are some of the 79 competitors of Alligator Bioscience.

  • What is Alligator Bioscience’s annual earnings per share (EPS)?

    Alligator Bioscience’s EPS for 12 months was -$0.06.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process